SIREN : 445259179
PHARMA 10 is a French company founded 23 years ago, specialized in the sector Centrales d'achat non alimentaires. Based in ROMILLY-SUR-SEINE (10100), this company of category PME shows in 2024 a revenue of 16.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 490 450 € | 15 769 494 € | 16 649 251 € | 16 487 314 € | 15 547 678 € | 12 612 777 € | 11 983 534 € | 11 002 398 € | 10 764 825 € |
| Net income | 1 695 655 € | 1 659 622 € | 1 675 622 € | 1 521 471 € | 1 409 581 € | 997 396 € | 1 140 592 € | 1 036 364 € | 1 099 238 € |
| EBITDA | 2 469 438 € | 2 326 549 € | 2 370 209 € | 2 188 762 € | 2 050 264 € | 1 599 292 € | 1 578 331 € | 1 605 079 € | 1 637 207 € |
| Net margin | 10.3% | 10.5% | 10.1% | 9.2% | 9.1% | 7.9% | 9.5% | 9.4% | 10.2% |
In 2024, PHARMA 10 achieves revenue of 16.5 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.5%. Vs 2023: +5%. After deducting consumption (12.2 M€), gross margin stands at 4.3 M€, i.e. a rate of 26%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.5 M€, representing 15.0% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.7 M€, i.e. 10.3% of revenue. This profit can be retained or distributed to shareholders.
16 490 450 €
4 260 339 €
2 469 438 €
2 206 442 €
1 695 655 €
15.0%
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 65%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 11.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
11.248%
64.745%
11.746%
0.198
52.1%
In 2024, the debt ratio of PHARMA 10 (11.25) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of PHARMA 10 (64.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of PHARMA 10 (0.20) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 289.05. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.3x. Danger: operating income does not cover interest charges, unsustainable situation.
289.051
0.287
In 2024, the liquidity ratio of PHARMA 10 (289.05) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of PHARMA 10 (0.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 48 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 43 days. The company must finance 5 days of gap between collections and payments. Inventory turnover is 54 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 103 days of revenue, i.e. 4.7 M€ to permanently finance. Over 2016-2024, WCR increased by +73%, requiring additional financing.
4 712 146 €
48 j
43 j
54 j
103 j
Based on 85 transactions of similar company sales
(all years),
the value of PHARMA 10 is estimated at
3 279 162 €
(range 1 779 345€ - 11 571 387€).
With an EBITDA of 2 469 438€, the sector multiple of 1.0x is applied.
The price/revenue ratio is 0.32x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMA 10 with other companies in the same sector:
Voir toutes les statistiques du secteur Centrales d'achat non alimentaires
The revenue of PHARMA 10 in 2024 is 16.5 M€.
Yes, PHARMA 10 generated a net profit of 1.7 M€ in 2024.
The headquarters of PHARMA 10 is located in ROMILLY-SUR-SEINE (10100), in the department Aube.
The tax return of PHARMA 10 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMA 10 operates in the sector Centrales d'achat non alimentaires (NAF code 46.19A). See the 'Sector positioning' section above to compare the company with its competitors.